BR0215588A - Compostos imunoefetores - Google Patents

Compostos imunoefetores

Info

Publication number
BR0215588A
BR0215588A BR0215588-5A BR0215588A BR0215588A BR 0215588 A BR0215588 A BR 0215588A BR 0215588 A BR0215588 A BR 0215588A BR 0215588 A BR0215588 A BR 0215588A
Authority
BR
Brazil
Prior art keywords
compounds
present
immunoefector
antigen
methods
Prior art date
Application number
BR0215588-5A
Other languages
English (en)
Inventor
David A Johnson
Jory R Baldridge
Greg Sowell
Christopher W Cluff
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of BR0215588A publication Critical patent/BR0215588A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"COMPOSTOS IMUNOEFETORES". A presente invenção provê compostos contendo uma 2-desóxi-<225>D-glucopiranose (glucosamina) glicosidicamente ligada a um grupo aminoalquila (aglicon) cíclico. A invenção ainda provê métodos para indução de uma resposta imune usando os compostos da presente invenção na presença ou ausência de um antígeno. Em adição, métodos para tratamento de doença com os compostos da presente invenção com ou sem um antígeno também são providos nesta invenção.
BR0215588-5A 2002-02-04 2002-02-04 Compostos imunoefetores BR0215588A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/003580 WO2003065806A1 (en) 2002-02-04 2002-02-04 New immunoeffector compounds

Publications (1)

Publication Number Publication Date
BR0215588A true BR0215588A (pt) 2005-03-22

Family

ID=27732075

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215588-5A BR0215588A (pt) 2002-02-04 2002-02-04 Compostos imunoefetores

Country Status (19)

Country Link
EP (1) EP1482795B1 (pt)
JP (1) JP2005516980A (pt)
KR (1) KR100885008B1 (pt)
CN (1) CN1301134C (pt)
AT (1) ATE447844T1 (pt)
AU (1) AU2002253909B2 (pt)
BR (1) BR0215588A (pt)
CA (1) CA2474398A1 (pt)
CY (1) CY1109692T1 (pt)
CZ (1) CZ2004862A3 (pt)
DE (1) DE60234386D1 (pt)
DK (1) DK1482795T3 (pt)
ES (1) ES2336080T3 (pt)
HU (1) HUP0500539A2 (pt)
IL (1) IL163304A (pt)
MX (1) MXPA04008559A (pt)
NO (1) NO20043707L (pt)
PT (1) PT1482795E (pt)
WO (1) WO2003065806A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
EP1482955B1 (en) * 2002-02-04 2013-12-25 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
CN101378778B (zh) 2005-12-22 2013-02-06 葛兰素史密丝克莱恩生物有限公司 肺炎球菌多糖缀合物疫苗
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20100021424A1 (en) 2006-06-02 2010-01-28 Vincent Brichard Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
JP2010531330A (ja) 2007-06-26 2010-09-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
EP2201131B8 (en) 2007-09-17 2014-12-10 MDxHealth SA Improved methylation detection
CN102575284A (zh) 2009-03-17 2012-07-11 MDx健康公司 改进的基因表达检测
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN114302737A (zh) * 2019-05-20 2022-04-08 索利吉尼克斯公司 制造三价线状病毒疫苗的组合物和方法
CN114206909A (zh) 2019-07-21 2022-03-18 葛兰素史克生物有限公司 治疗性病毒疫苗
EP4161570A1 (en) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Modified betacoronavirus spike proteins
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6013640A (en) * 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US6699846B2 (en) * 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
DE60118207T2 (de) * 2000-08-04 2006-11-09 Corixa Corp., Seattle Neue immunoeffectorverbindungen
EP1482955B1 (en) * 2002-02-04 2013-12-25 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds

Also Published As

Publication number Publication date
AU2002253909A1 (en) 2003-09-02
ES2336080T3 (es) 2010-04-08
CZ2004862A3 (cs) 2005-01-12
CY1109692T1 (el) 2014-08-13
IL163304A (en) 2010-11-30
DE60234386D1 (de) 2009-12-24
JP2005516980A (ja) 2005-06-09
WO2003065806A1 (en) 2003-08-14
HUP0500539A2 (en) 2006-09-28
ATE447844T1 (de) 2009-11-15
EP1482795A1 (en) 2004-12-08
EP1482795A4 (en) 2006-08-09
CN1301134C (zh) 2007-02-21
NO20043707L (no) 2004-09-03
AU2002253909B2 (en) 2008-06-05
PT1482795E (pt) 2010-02-09
DK1482795T3 (da) 2010-02-01
EP1482795B1 (en) 2009-11-11
KR100885008B1 (ko) 2009-02-20
CA2474398A1 (en) 2003-08-14
CN1622754A (zh) 2005-06-01
MXPA04008559A (es) 2004-12-06
KR20040083433A (ko) 2004-10-01

Similar Documents

Publication Publication Date Title
ATE321063T1 (de) Neue immunoeffectorverbindungen
BR0215588A (pt) Compostos imunoefetores
BR0108713A (pt) Expressão hìbrida de proteìnas de neisseria
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
BRPI0408085A (pt) composição e método para o tratamento e prevenção de infecções entéricas bacterianas
MY172641A (en) High concentration antibody and protein formulations
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
BR0214457A (pt) métodos para o tratamento de cáncer
TR200103018T2 (tr) İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
BR0213207A (pt) remodelagem e glicoconjugação de peptìdeos
AR063315A2 (es) Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus
BR0015501A (pt) Compostos de aminoalquil glucosaminida fosfato e uso dos mesmos como adjuvantes e agentes de efeito imune
BRPI0509139A (pt) composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor
BR0309809A (pt) indução de toleráncia imunológica especìfica quanto ao antìgeno
BR0307788A (pt) método de redução e tratamento de imunossupressão induzida por uv-b
BR9808772A (pt) Composição de vacina multivalente com carreadora misturada
BR0313251A (pt) Métodos de extração de polìmero
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
BRPI0407207A (pt) Método para tratar, prevenir e diagnosticar uma infecção por heliocobacter
BRPI0512413A (pt) derivados de polissacarìdeo e usos na indução de uma resposta imune
BR0214884A (pt) Derivados de 7-amino-benzotiazol como ligantes do receptor de adenosina
BR0211922A (pt) Método para secagem de artigos de tecido contendo fluido lipofìlico, sistema de secagem dos referidos artigos, bem como artigo de tecido assim obtido
BR0315178A (pt) Eritropoietina: remodelagem e glicoconjugação de eritropoietina
BR0211830A (pt) Dose única de azitromicina
ES2096988T3 (es) Organopolisiloxanos que contienen grupos hidrofilos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.